Increasing adherence for patients with Psoriasis and Psoriatic arthritis
This Master Thesis was made under and in collaboration with Pond Healthcare Innovation for Celgene. Celgene is a global pharmaceutical company developing treatments for cancer and other severe, immune, inflammatory conditions. In March 2015 Celgene launched a new oral treatment called Otezla (effective substance aprimelast) on the Nordic market. With this move they entered the arena of Psoriasis a
